Availability on line of the sanofi-aventis half-year financial report for 2007
- Details
- Category: Sanofi
Sanofi-aventis announces that its half-year financial report for 2007 is now available. This document may be downloaded from the "Investors" page, under the heading "Regulated Information" found on the companyâs corporate website.
Merck Announces Fourth Quarter 2007 Dividend
- Details
- Category: Merck
The Board of Directors of Merck & Co., Inc., meeting today, declared a quarterly dividend of $0.38 per share on the Company's common stock for the fourth quarter of 2007. The $0.38 per share dividend is payable on Oct. 1, 2007 to stockholders of record at the close of business on Sept. 7, 2007.
Key business with prescription medicines continues to boost growth at Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim again posted good business results for the first six months of 2007. The company grew by 2.1% in euro terms compared to EUR 5,296 million in 2006, achieving net sales of EUR 5,407 million. Currency-adjusted growth was 7.5%.
New Spiriva® Respimat® inhaler completes European approval process for COPD
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market Spiriva® Respimat® in the European Union for people with chronic obstructive pulmonary disease (COPD). This positive opinion for the Spiriva® Respimat® is the cornerstone of all national approvals in 25 countries of the European Union. Spiriva® Respimat® is a propellant-free, new generation inhaler that combines innovative technology with the proven efficacy of Spiriva® (tiotropium).
Boehringer Ingelheim announces first international head-to-head trial of Aptivus®
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety of Aptivus® (tipranavir) versus darunavir, both with ritonavir as part of combination antiretroviral therapy. POTENT will include 800 treatment-experienced patients in 15 countries. The primary endpoint is time to virologic failure, with a secondary endpoint of virologic response at 48 weeks of treatment.
Recommendation of Approval for the Merz Botulinum Neurotoxin Typ A in European Countries
- Details
- Category: Product
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) in London recommended the approval of the Merz- developed product Botulinum neurotoxin Type A. Merz is expecting approval in ten European countries within the next few months. The company already received approval in Denmark and Sweden.
The U.S. Launch of Neupro® for the Treatment of Early-Stage Parkinson's Disease
- Details
- Category: Product
UCB and SCHWARZ PHARMA announced today that Neupro® (Rotigotine Transdermal System), a new once-daily transdermal dopamine agonist approved for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease, is now commercially available in retail pharmacies throughout the United States. Neupro® will be co-promoted by UCB and SCHWARZ PHARMA. These companies have dedicated sales forces that will immediately begin reaching out to physicians who treat Parkinson's disease nationwide.
More Pharma News ...
- Novartis Completes Divestment of Medical Nutrition Business
- Sandoz Receives Positive EU Opinion for Approval of epoetin alfa biosimilar
- Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL®
- UK Body Recommends Pfizer's Champix (varenicline) for Smokers
- JANUVIA Approved in the European Union for the Treatment of Type 2 Diabetes